A pharmaceutical composition comprising 3,4dihydro-3-methy1-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine 8-carboxylate

Abstract

The present invention discloses a pharmaceutical composition having activity of anti-tumor comprising a therapeutically effective amount of one or more compounds of formula I as the active ingredient, conventional pharmaceutically acceptable carriers, and one or more pharmaceutically acceptable acidic components, wherein said acidic component is selected from a group consisting of oleic acid, stearic acid, linolenic acid, fumaric acid, benzoic acid, tartaric acid, sorbic acid, lactic acid, citric acid, acetic acid and EDTA, wherein X is 0 or S; R is substituted or unsubstituted C3˜C10 straight or branched alkyl, C3˜C10 cycloalkyl, C3˜C10 straight or branched alkenyl or C3˜C10 straight or branched chain alkynyl; and if R has substituting group, said substituting group may be C1˜C6 alkyl, C1˜C6 alkoxy, C1˜C6 alkylthio group, C1˜C6 alkyl amino group, phenyl or phenyl substituted by halogen. Further, said composition may be made into all sorts of conventional dosage forms, in particular the oral dosage forms and topically administered transdermal dosage form. In addition, the invention discloses a method to use the composition for treatment of tumor.